Apoptotic signatures allow early and rapid screening of drug-induced liver injury to accelerate drug discovery
Using AEGIS early in drug discovery exemplifies a more efficient approach to identify and mitigate potential safety concerns. This can reduce the need for animal testing, and accelerates drug discovery, ultimately providing the right medicines to patients more quickly.
Authors
- Marie Kalm (ORCID: https://orcid.org/0000-0002-0680-5040)
- John Hellgren (ORCID: https://orcid.org/0000-0003-3317-7737)
- Aydar Uatay (ORCID: https://orcid.org/0000-0002-5233-1691)
- John Gallon (ORCID: https://orcid.org/0000-0002-5328-6298)
- F. Anders Karlsson (ORCID: https://orcid.org/0009-0005-7086-0975)
- P. U. Andersson
- Naoko Toki (ORCID: https://orcid.org/0000-0003-4364-3631)
- Ramy Elgendy (ORCID: https://orcid.org/0000-0002-2592-3448)
- Dominic P. Williams (ORCID: https://orcid.org/0000-0002-0758-3152)
- Bhavik Chouhan
- Johanna Sagemark
- Jennifer Y. Tan (ORCID: https://orcid.org/0000-0003-1064-1162)
- Kenneth R. Pryde (ORCID: https://orcid.org/0000-0001-8241-2671)
- Aditi Chaudhari
- Bino John
- Alessandro Bonetti
- Julia Lindgren
Institutions
- AstraZeneca (United Kingdom) (GB)
- AstraZeneca (South Korea) (KR)
- AstraZeneca (Australia) (AU)
- AstraZeneca (Brazil) (BR)
- AstraZeneca (Poland) (PL)
- AstraZeneca (Finland) (FI)
- AstraZeneca (Sweden) (SE)
Publication Details
- Journal
- Communications Medicine
- Published
- 2025-12-24
- DOI
- https://doi.org/10.1038/s43856-025-01306-7
- Primary Topic
- Drug-Induced Hepatotoxicity and Protection
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases